Product Approval Information
Proper Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
Tradename: Pentacel
Manufacturer: Sanofi Pasteur Limited, License #1726
STN: 125145/0
Approval Date: 6/20/2008
Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®.
Approval information/letter/labeling
Memorandum/Reviews
- Summary Basis for Regulatory Action
- Clinical Review (PDF - 1.4 MB)
- Clinical: Review of Methods for Pertussis Clinical Serology (PDF - 452 KB)
- Evaluation of Proposed Proprietary Name Pentacel
- Immunogenicity Review (PDF - 1.5 MB)
- Post Licensure Safety Surveillance Study of Routine Use of Pentacel (PDF - 250 KB)
- Product Review of Haemophilus Component and Serology (PDF - 387 KB)
- Recommendations Regarding Request for Partial Waiver of Pediatric Studies
- Review of CMC and Serology of Diphtheria and Tetanus Toxoids (PDF - 222 KB)
- Statistical Review and Evaluation (PDF - 188 KB)
- Surveillance for Rates of Hib Disease Among Persons Aged 0-4 Years Receiving Pentacel or Other Hib Vaccines (PDF - 374 KB)
- Surveillance for Rates of Pertussis Disease Among Persons Aged 0-4 Years Receiving Pentacel or Other Pertussis Vaccines (PDF - 279 KB)
- 6/17/2008 Memo (PDF - 92 KB)
- 5/20/2008 Review Memo
- 2/26/2007 Review Memo (PDF - 200 KB)
- 2/20/2007 Review Memo (PDF - 211 KB)
- 2/14/2007 Review Memo
- 11/27/2006 Review Memo (PDF - 355 KB)
- 4/7/2006 Review Memo (PDF - 411 KB)
- 3/27/2006 Review Memo (PDF - 1.8 MB)
Administrative Documents
Correspondence